EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated CLL

Pinterest LinkedIn Tumblr +

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) is effective in treating patients with chronic lymphocytic leukaemia (CLL), and patients with mutated IGHV have favourable long-term outcomes.

In a Phase II study led by MD Anderson, researchers evaluated the efficacy of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) ­— a chemoimmunotherapy and targeted therapy combination — in 45 previously untreated patients with IGHV-mutated CLL. Nitin Jain, M.D., reported on the long-term outcomes of the study after a median follow-up of 56.8 months.

After just three cycles, 87% of patients had undetectable measurable residual disease (U-MRD), with improved responses after continued therapy.

The five-year progression-free survival (PFS) and overall survival (OS) were 97.7% and 97.8%, respectively. One patient had CLL progression.

No patient had Richter’s transformation. The findings reveal that iFCG offers high rates of U-MRD remission and long-term survival with only three cycles of chemotherapy, as opposed to previous treatments with six cycles of chemotherapy.

Source: The University of Texas MD Anderson Cancer Center


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.